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Aniridia (OMIM 106210) is a congenital developmental 
disorder of the eye characterized by bilateral complete or 
partial iris hypoplasia [1]. Associated ocular anomalies 
include foveal hypoplasia, nystagmus, corneal opacification 
and neovascularization, cataracts, and glaucoma, which can 
lead to progressive decreased visual acuity [2,3]. Aniridia 
is a rare disease, with an incidence of between 1:64,000 and 
1:100,000 births [4-6]. Isolated aniridia is caused by sequence 
variants in the PAX6 gene [7] (OMIM 607108) or chromo-
somal rearrangements involving PAX6, and is transmitted in 
an autosomal dominant manner with complete penetrance 
but variable expressivity. Aniridia is usually isolated but 
in some cases can be part of a contiguous gene syndrome, 
such as Wilms tumor, aniridia, genitourinary abnormalities, 
and mental retardation (WAGR; OMIM 194072) syndrome 
caused by hemizygous deletions of chromosome 11p13 
involving PAX6 and the adjacent Wilms tumor (WT1; OMIM 
607102) gene [8], or Wilms tumor, aniridia, genitourinary 
anomalies, mental retardation, and obesity (WAGRO; OMIM 
612469) syndrome involving hemizygous deletion of the 
region containing PAX6, WT1, and BDNF (OMIM 113505) 
associated with obesity [9].
The PAX6 gene, which lies on chromosome 11p13, 
encodes a highly conserved transcription factor containing 
two DNA-binding domains (a paired domain and a paired-
type homeodomain) and a proline-serine-threonine-rich 
transactivation domain [10]. PAX6 is expressed in the 
ectoderm, and subsequently in the differentiating cells of 
the cornea, lens, ciliary body, and retina [11]. Heterozygous 
variants in PAX6 in mice result in a small eye phenotype (Sey) 
whereas homozygous variants result in anophthalmia and 
poorly formed nasal cavities [12]. The phenotypes observed in 
humans and mice with PAX6 haploinsufficiency demonstrate 
that the gene has a pivotal role in the embryological develop-
ment of the eye, especially the anterior segment structures.
The human PAX6 allelic variant database (last 
accessed 19 January 2018) contains 472 unique variants of 
PAX6. Several types of PAX6 variants are associated with 
aniridia, including nonsense, splicing, frameshift, missense, 
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extension variants, and in-frame insertions or deletions [13]. 
The majority of sequence variants associated with isolated 
aniridia are loss of function variants (nonsense, splice, 
frameshift variants, and in-frame insertions or deletions) 
that introduce premature termination codons into the PAX6 
coding region and potentially result in the degradation of the 
translation products by the nonsense-mediated decay process 
to prevent the production of truncated proteins [13]. There-
fore, the phenotype results from haploinsufficiency of the 
PAX6 gene. Sequence variants and deletions of the PAX6 gene 
account for around 90% of all cases of familial or sporadic 
aniridia [14,15]. Aniridia may also result from chromosomal 
rearrangements involving elements with transcriptional func-
tions downstream of PAX6 without affecting the integrity of 
the structural PAX6 gene [16,17].
This study reported on the largest cohort from Australia 
and is the first study of patients with aniridia from Cambodia, 
Sri Lanka, Bhutan, and New Caledonia. We investigated 
PAX6 for sequence variants and deletions in 18 probands with 
aniridia and 11 of their affected relatives. We identified vari-
ants and deletions in PAX6 in 94% of the probands, including 
four novel PAX6 deleterious variants, and reported detailed 
associated phenotypes.
METHODS
Participant recruitment: Twenty-nine individuals from 18 
families were enrolled. The study complied with the tenets of 
the Declaration of Helsinki and the Association for Research 
in Vision and Ophthalmology (ARVO) statement on human 
subjects. Informed consent was obtained from participants or 
their legal guardian in the local language. Institutional board 
approval was obtained from the Southern Adelaide Clinical 
Human Research Ethics Committee, and further approval 
was obtained from local institutions in Cambodia, Bhutan, 
and Sri Lanka.
Most Australian and New Caledonian cases were part 
of the Australian and New Zealand Registry of Advanced 
Glaucoma as described previously [18]. They received a 
complete ocular examination, including corrected visual 
acuity, slit-lamp biomicroscopy of the anterior segment, and 
review of the fundus. In children, when performed, refraction 
was measured with a retinoscope following cycloplegic dila-
tion with 1% cyclopentolate. Central corneal thickness (CCT) 
was measured in a minority of patients using an ultrasound 
pachymeter (Pachymate, DGH Technology, Exton, PA).
Fifteen patients from seven families were enrolled as a 
result of surveys of schools for the blind in Cambodia [19], 
Sri Lanka [20], and Bhutan [21] that evaluated the causes of 
childhood blindness within those communities. Data were 
collected from school staff, children, relatives, and medical 
records. A detailed eye examination was conducted by a team 
of Australian and local optometrists and ophthalmologists 
as previously described [19–21]. Briefly, the examination 
included assessment of near and distance visual acuity, the 
anterior segment was assessed with slit-lamp biomicroscopy, 
and the posterior segment was evaluated with indirect or 
direct fundus ophthalmoscopy. Children who had distance 
vision recorded as better than no perception of light under-
went refractive testing and low-vision assessment. Four 
affected relatives of a family from Bhutan provided samples 
for DNA analysis but could not be examined.
Genetic analysis: DNA was extracted from whole blood 
anticoagulated with EDTA using the QIAcube (Qiagen, 
Doncaster, Australia) automated system and reagents 
according to the manufacturer’s protocols. Alternatively, 
for patients either needle phobic or remote from a pathology 
collection center, including Cambodian, Bhutanese, and Sri 
Lankan participants, individuals provided a saliva specimen 
collected in an Oragene® DNA Self-Collection Kit (DNA 
Genotek Inc., Kanata, Canada), and the DNA was extracted 
according to the manufacturer’s instructions. The entire 
coding sequence and intron–exon boundaries of PAX6, 
encoding the longer transcript NM_001604.5, was ampli-
fied with PCR using primer pairs detailed in Appendix 1. 
Each PCR was performed using 100 ng of purified genomic 
DNA as a template in a reaction mix containing 1X final 
concentration of AmpliTaq Gold 360 Master Mix. The 
following PCR conditions on a Veriti (Life Technologies, 
Mulgrave, Australia) thermal cycler were used as standard 
for all templates with both primer pairs: Step 1, 95 °C for 10 
min; Step 2, 95 °C for 30 s, 55 °C for 30 s, 72 °C for 1 min, 
repeated for 40 cycles; and Step 3, 72 °C for 7 min. PCR 
amplified products were prepared for DNA sequencing with 
the ExoSAP method using a 10 μl sample of each PCR reac-
tion treated with 5 U of Exonuclease I (Biolabs, Ipswich, MA) 
and 1 U of Shrimp Alkaline Phosphatase (USB Corporation, 
Cleveland, OH) to remove residual primers and dNTPs. 
Bidirectional BigDye® Terminator Cycle Sequencing (Life 
Technologies) reactions of the appropriate template and PAX6 
PCR primer were resolved and base called on an Applied 
Biosystems 3130XL Genetic Analyzer (Life Technologies).
Detection of the sequence variants was performed using 
Mutation Surveyor™ v4.0.11 (SoftGenetics LLC, State 
College, PA). All forward and reverse sequence trace files 
were assembled by the program against the PAX6 GenBank 
reference (assembly GRCh37.p13). Software programs Sorting 
Intolerant From Tolerant (SIFT) and PolyPhen-2 HumVar 
were used to predict the potential impact of amino acid 
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substitutions on the protein. Conservation among mammalian 
species was assessed using Homologene. Genome Aggrega-
tion Database r2.0.2 (gnomAD) was used to compare allelic 
frequencies to the population frequencies.
PAX6 was analyzed for copy number variation (CNV) 
with multiplex ligation-dependent probe amplification 
(MLPA) using the SALSA MLPA P219-B2 PAX6 probemix 
(MRC Holland, Amsterdam, the Netherlands) according to 
the manufacturer’s instructions. The copy number present in 
the original DNA specimen was determined from the relative 
amplitude of each amplicon product detected using the ABI 
3130xl Genetic Analyzer and the data analyzed using Peak 
Scanner v2.0 (ThermoFisher Scientific, Scoresby, Australia). 
Breakpoints of the identified PAX6 deletions were further 
characterized using single nucleotide polymorphism (SNP) 
array (Illumina Infinium CytoSNP-850K BeadChip, Illumina 
PTY, Scoresby, Australia) in some patients. The SNP array 
was also performed for individual 13 following inconclusive 
MLPA results. Mosaic changes were detected by assessing 
for changes in probe intensities along with a shift in the allele 
frequencies of the SNP probes as previously described [22]. 
The percentage of mosaicism was estimated by comparing the 
expected allele frequency under a deletion model to various 
mosaic levels [22].
Data were analyzed with PASW Statistics, Rel. 
18.0.1.2009 (SPSS Inc., Chicago, IL). Data are presented as 
mean ± standard deviation. The Mann–Whitney U test was 
used for the assessment of differences in nonparametric data. 
A p-value ≤ 0.05 was considered significant.
RESULTS
Phenotype: Twenty-nine patients from 18 families were 
evaluated in this study, comprising 14 male and 15 female 
patients. The mean age of the whole cohort was 26.4±14.9 
years (range 9–58 years), while the mean age of the Austral-
asian cohort was 31.2±15.9 years (range 11–58 years) and the 
mean age of the Southeast Asian cohort was 19.9±11.3 years 
(range 9–51 years). The age difference is explained by the 
fact that patients from Southeast Asia were children recruited 
from schools for the blind. The phenotype of the 25 exam-
ined individuals is described in Table 1. A family history of 
aniridia was reported in 10/18 probands (56%). Additional 
family members were available for genetic testing for five of 
the probands, and the pedigrees are illustrated in Figure 1A.
All individuals had total iris aplasia based on available 
documentation. Some of the most commonly associated 
complications are shown in Figure 2. After iris anomalies, 
the most commonly associated features were foveal hypo-
plasia (14/18, 78%) and nystagmus (17/19, 90%). Cataract or 
a history of cataract extraction was identified in 72% (18/25). 
Cataract extraction was performed in 50% (9/18) with a mean 
age at surgery of 20.4±13.9 years. Posterior subcapsular or 
cortical and posterior subcapsular cataracts were the predom-
inant forms of lenticular opacification. Subluxation of the 
lens was identified in 36% (9/25). Glaucoma was identified 
in 44% (11/25), and glaucoma filtration surgery or glaucoma 
drainage device implantation was required by 36% (4/11) with 
a mean age at glaucoma surgery of 13.0±5.60 years. CCT 
was obtained in 12 individuals; the mean CCT was high at 
645±74.0 μm (range 526–779 μm). Keratopathy was present 
in 48% (12/25; Figure 2), including one individual with limbal 
stem cell failure and complete corneal opacification who 
required corneal transplantation (1/12, 8%). The mean age at 
keratopathy diagnosis was 19.3±10.5 years (range 9–34 years). 
A range of refractive errors were identified within the cohort 
with refraction ranging from −13.00 to +7.30 (excluding indi-
viduals 15, 16, and 17 who had refractions of +8.00 to +11.00 
secondary to subluxed lenses). All individuals from family 
12 were myopic, including two individuals (12a and 12c) with 
high myopia associated with chorioretinal atrophy affecting 
the macula. Visual acuity ≤ 1.00 logMAR was recorded in 
65% (31/48) of eyes, including 40% (8/20) of eyes from indi-
viduals aged ≤20 years compared with 82% (23/28) of eyes 
from individuals aged >20 years.
The prevalence of keratopathy was statistically signifi-
cantly higher in the Australasian cohort (11/14, 78.6%) than 
in the Southeast Asian cohort (1/11, 9.1%, p=0.002). The 
prevalence of other aniridia-associated features, including 
foveal hypoplasia, nystagmus, cataracts, lens dislocation, 
and glaucoma, were not statistically significantly different 
between the two cohorts.
PAX6 genetic results: Sequence variants in the PAX6 gene 
were found in 11 of the 18 probands (61.1%) and included 
seven previously reported and four novel variants. Eight 
variants were predicted to introduce a premature termina-
tion codon, one variant resulted in a C-terminal extension 
variant, one variant affected the initiation codon, and one was 
a missense variant (Table 2). Chromosomal deletions were 
found in an additional six probands (33.3%). No sequence 
variants or deletions in PAX6 were identified in individual 14. 
In total, PAX6 accounted for 94.4% (17/18) of the probands 
with aniridia in this study.
Among the eight variants predicted to result in premature 
termination codons, five were nonsense variants, two were 
frameshift variants, and one was a splicing variant (Table 
2). Two were novel, p.(Pro81HisfsTer12) and p.(Gln74Ter), 
whereas the remainder have been previously reported. 
Variant p.(Pro81HisfsTer12) segregated in two affected family 
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members of individual 1a and was absent from his maternal 
grandparents. The variant was confirmed to be de novo with 
molecular analysis (Figure 1B). Splicing variant c.1183+1G>A 
was predicted to result in the loss of the last exon. One variant 
was predicted to result in a string of lysine extension at the 
end of the PAX6 protein (p.(Ter423LeuextTer15)), leading to 
translation into the 3′ untranslated region (UTR). This variant 
was present in individual 12a from Cambodia and segregated 
in four affected children. Variant p.(Met1?) affected the initia-
tion codon, was novel, and was considered deleterious. The 
Figure 1. Pedigrees and genetic analysis. A: Pedigree of the families recruited. Round symbols indicate female; square, male; diamond, 
unspecified gender; fully filled symbols, aniridia; unfilled symbols, unaffected; arrow, proband; plus/minus, presence/absence of the familial 
PAX6 variant. B: PAX6: c.238_241dupACTC, p.(Pro81HisfsTer12) sequence variant in affected individual 1c (at the top) and her unaffected 
grandparents 1d and 1e (at the bottom). The black arrow marks the heterozygous variant.
Molecular Vision 2018; 24:261-273 <http://www.molvis.org/molvis/v24/261> © 2018 Molecular Vision 
267
removal of the initiation codon is expected to result in an 
absence of translation or translation starting at a cryptic site 
downstream and resulting in a truncated protein missing the 
N-terminal region that includes the paired DNA-binding 
domain. Finally, the missense variant, p.(Ile29Thr), has not 
been previously reported in the literature and was not present 
in the gnomAD populations database. The missense variant 
was predicted to be deleterious by SIFT and PolyPhen-2, and 
was highly conserved among species. As a result, this novel 
variant was regarded as affecting protein function.
Figure 2. Clinical photographs of 
the eyes of individuals with aniridia. 
A: Slit-lamp photo showing total 
aniridia (individual 5). B: Slit-lamp 
retroillumination photo showing 
total aniridia (individual 2). C: 
Slit-lamp retroillumination photo 
showing polar cataract (individual 
5). D: Slit-lamp retroillumina-
tion photo showing anterior polar 
and cortical cataract (individual 
7). E: Slit-lamp retroillumination 
photo showing lens subluxation 
(individual 1b). F: Slit-lamp photo 
showing opacification and vascular-
ization of the cornea due to limbal 
stem cell failure (individual 1b). 
G: Fundus photography showing 
small and tilted disc (individual 2). 
H: Fundus photography showing 
macular hypoplasia (individual 2).
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The six chromosomal deletions are described in Table 3. 
MLPA of the PAX6 gene revealed a partial terminal deletion 
involving exons 14 and 15 of the gene in individual 3a that 
segregated in the proband’s affected daughter (3b). The WT1 
gene is proximal of PAX6 and therefore, was not deleted. The 
karyotype of individual 7 revealed a deletion of the short arm 
of chromosome 11 (del11(p13-p15)). Heterozygous deletion of 
the entire PAX6 gene was confirmed with MLPA. This patient 
was obese (weight >90th percentile) and had mild intellectual 
impairment and immunoglobulin A (IgA) nephropathy in 
addition to the typical features of aniridia, compatible with 
a diagnosis of WAGRO syndrome. The SNP array of indi-
viduals 16 and 18 revealed a deletion of 795 kb and 503 kb 
of chromosome 11, respectively, both encompassing PAX6 
but not the WT1 gene. The SNP array of individual 13 identi-
fied a 480 kb deletion of chromosome 11 that was 100 kb 
distal of the PAX6 gene. Finally, the SNP array of individual 
5 identified a 96 kb interstitial deletion at chromosome 11p13 
involving PAX6 but not WT1. The expected probe intensities 
showed a decrease that was less than the expected decrease 
for a complete loss of one copy of the region, and the allele 
frequency differed from what was expected under a deletion 
model, both suggesting mosaicism. The estimated level of 
mosaicism for the deleted cell line was 30%. There was no 
association with the aniridia-associated features or the visual 
acuity between individuals with deletions in PAX6 compared 
with those with sequence variants after accounting for age.
DISCUSSION
Phenotype: Variants in the PAX6 gene have been identified in 
individuals with aniridia from different populations [14,23-
25]. This study is the largest study that includes patients with 
aniridia from Australia, and the first report of patients with 
aniridia from New Caledonia, Cambodia, Sri Lanka, and 
Bhutan. Aniridia is an autosomal dominant disorder with 
high penetrance but variable expressivity [26]. Abnormalities 
of the iris are the most common feature of aniridia, and are 
characterized by either the absence of a visible iris or rudi-
mentary remnant. Foveal hypoplasia is present in the majority 
Table 2. sequence varianTs idenTified in The PAX6 gene in Probands.
Proband ID Location Domain Nucleotide change Amino acid change References
1a Exon 6 PD c.238_241dupACTC p.(Pro81HisfsTer12) Novel
2 Exon 5 PD c.114_121del8 p.(Pro39HisfsTer14) [1]
4 Exon 10 PST c.820C>T p.(Gln274Ter) Novel
6 Exon 5 PD c.86T>C p.(Ile29Thr) Novel
8 Exon 8 LNK c.538C>T p.(Gln180Ter) [2]
9 Exon 6 PD c.325G>T p.(Gly109Ter) [3]
10 Exon 10 HD c.781C>T p.(Arg261Ter) [1,3-5]
11 Exon 8 LNK c.607C>T p.(Arg203Ter) [2,4-7]
12a Exon 13 PST c.1268A>T p.(Ter423LeuextTer15) [1,3,5,8]
15 Exon 1 - c.3G>T p.(Met1?) Novel
17 Intron 12 PST c.1183+1G>A - [5]
HD, homeodomain; LNK, linker region; PD, paired domain; PST, proline-threonine-serine-rich domain
Table 3. 11P13 deleTions idenTified in Probands.
Proband ID Method Deletion (hg19) Comments
3a MLPA c.(?_858)_(1207_?)del Deletion of exons 14 & 15 of PAX6
5 MLPA+SNP array 31,742,816–31,838,768 96kb deletion involving PAX6 in mosaic
7 Karyotype+MLPA del11(p13-p15) Deletion involving PAX6, WT1 and BDNF
13 MLPA+SNP array 31,225,707–31,705,767 480kb deletion distal of PAX6
16 MLPA+SNP array 31,488,890–32,249,249 795kb deletion involving PAX6
18 MLPA+SNP array 31,530,678–32,033,826 503kb deletion involving PAX6
MLPA: Multiplex Ligation-dependent Probe Amplification
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of patients [2,23,27], as shown in this study (78%), and results 
in decreased visual acuity and nystagmus [1]. Progressive loss 
of visual function often results from complications, such as 
cataracts, glaucoma, and corneal opacification, that lead to 
worsened vision with increasing age. In this cohort, vision ≤ 
1.00 logMAR defined as severe visual impairment according 
to the World Health Organization [28] was present in 65% of 
eyes, and visual acuity progressively deteriorated with age.
Cataract is the most common complication requiring 
surgery in aniridia, usually observed in 50–90% of patients 
[1-3,23,27,29,30]. Cataracts were present in 72% of the 
cohort. Small lens opacities may be present from birth, but 
they usually do not impair the vision until the teens or early 
adulthood [1,3]. This is reflected in the mean age of cata-
ract extraction at 20 years in this cohort. Lens dislocation 
is usually less common [3,23,30] but was present in 36% of 
the cohort.
The prevalence of glaucoma in aniridia is reported as 6% 
to 75% [1], although more recent studies suggest a prevalence 
around 45–65% [23,27,29,30] with an onset commonly in 
childhood or early adulthood [27,30]. Glaucoma was present 
in 44% of the cohort, and 36% needed glaucoma surgery at a 
mean age of 13 years. Glaucoma in aniridia is often difficult 
to treat and may require multiple interventions to control the 
intraocular pressure (IOP) to slow progression of the disease 
[31,32]. The mechanisms causing glaucoma in patients with 
aniridia are thought to result from developmental defects in 
the anterior chamber and impair the aqueous humor outflow 
through the trabecular meshwork and Schlemm’s canal. 
However, different explanations have been provided regarding 
the nature of these developmental defects, including progres-
sive angle closure and obstruction of the trabecular meshwork 
by the residual iris stroma extending anteriorly [33], absence 
of Schlemm’s canal [1], and abnormalities of the canal’s inner 
layer or the trabecular meshwork [32]. Heterozygous Pax6-
deficient mice show impaired development of the trabecular 
meshwork and Schlemm’s canal [34,35], and growing adhe-
sions between the cornea and the iris periphery, resulting in 
complete closure of the iridocorneal angle, increased IOP, and 
development of glaucoma [35].
The central corneal thickness influences IOP measure-
ments with thicker CCT leading to overestimation of IOP 
[36]. The mean CCT from individuals with aniridia in this 
study was high (645±74.0 μm) compared to the mean in 
healthy Australians (540±33.0 μm) [37] and in healthy Asian 
populations (504–556 μm) [37]. Other studies previously 
reported thick mean CCT measurements in children and 
adults with aniridia [15,27,38,39]. These findings indicate 
that IOP measurement can be less reliable in patients with 
aniridia and that examination of the optic nerve is important 
for detecting and managing patients’ glaucoma.
Aniridia-associated keratopathy is a serious complica-
tion developing in 50–90% of patients and has been reported 
as the most frequent complication by previous studies 
[23,27,29,40]. This complication often presents in late child-
hood or early adulthood and less commonly among younger 
patients [3,29]. In the present cohort, keratopathy was present 
in 48% of individuals with a mean age at diagnosis of 19 
years (range 9–34 years). Early features involve the periph-
eral epithelium, and aniridia-associated keratopathy leads to 
progressive opacification and vascularization of the cornea 
to complete corneal sclerosis and vascularization as the 
complication progresses centrally [29]. The keratopathy is 
believed to result from insufficiency of the limbal stem cell 
population [41]. Additionally, corneal surface problems may 
be complicated by abnormal tear film and Meibomian gland 
dysfunction [12]. In this study, keratopathy was more frequent 
in the Australasian cohort than in the Southeast Asian cohort. 
Although this may reflect true ethnic phenotypic variability, 
an alternative explanation could be reduced access to surgical 
procedures to address aniridia complications such as cataract, 
lens dislocation, and glaucoma, as surgical procedures are 
known to accelerate the development of keratopathy [42]. 
The latter explanation is supported by the finding that only 
one of the Southeast Asian individuals had a surgical proce-
dure (cataract surgery in one eye) and could account for the 
lower prevalence of keratopathy in this study compared with 
previous reports.
Genotype–phenotype correlations: We identified 11 different 
variants in PAX6, of which four were novel and eight intro-
duced a premature termination codon. A family history of 
aniridia was present in ten probands. A de novo inheritance 
was confirmed molecularly in one family. De novo variants in 
PAX6 have previously been reported although the prevalence 
is not known [2,43]. Similar to other studies [13-15], we did 
not find a statistically significant association between the 
phenotype of individuals with variants resulting in premature 
termination codons compared with individuals with deletions 
in PAX6. The absence of phenotypic difference is consistent 
with the fact that truncated proteins are subject to nonsense-
mediated decay [13], resulting in PAX6 haploinsufficiency 
in a similar manner to deletions in PAX6. Interestingly, 
nonsense suppression drugs have been shown to alter PAX6 
dosage, inhibit disease progression, and reverse some ocular 
phenotype in PAX6-transgenic mice [44]. This therapeutic 
approach is promising for PAX6-associated aniridia because 
the majority of cases are explained by variants resulting in 
premature termination codons.
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Although variants and gene deletions resulting in PAX6 
haploinsufficiency do not present genotype–phenotype corre-
lations, other types of PAX6 variants display associations. 
An extension variant, p.(Ter423LeuextTer15), resulting in a 
longer open reading frame and translation into the 3′ UTR, 
was identified in five affected individuals from the same 
family (individuals 12a–e). This variant has been reported 
among different populations with aniridia [14,15,25]. Partial 
aniridia and milder phenotypes have also been associated 
with PAX6 variants in the proline-threonine-serine-rich 
(PST) region [26]. However, none of the patients in this 
study with variants in the PST region had partial aniridia. 
Hingorani et al. reported that glaucoma was unusual and 
the iris anomalies were milder in individuals with exten-
sion variants in PAX6 compared to premature termination 
codon variants [2]. Interestingly, none of the five individuals 
carrying an extension variant in this study had glaucoma 
despite their age range (12–51 years) falling within the 
range of typical glaucoma onset. All individuals from this 
family had myopia, including three with high myopia (<–6.0 
diopters) and two with chorioretinal atrophy consistent with 
degenerative myopia. Other studies have also noted an asso-
ciation between PAX6-associated aniridia and high myopia 
[2,45]. Interestingly, myopia has been reported in other 
individuals with a similar C-terminal extension variant as 
family 12 [2]. A genome-wide association study previously 
identified significant linkage to myopia on chromosome 
11p13 in Caucasians, with strong evidence of linkage, but 
not association, for genetic markers covering the PAX6 gene 
[46]. Ng et al. identified two dinucleotide repeats in the PAX6 
P1 promoter that increased transcriptional activity of PAX6 
and were associated with high myopia in a Chinese popula-
tion [47]. Additional studies showed conflicting results for 
the association of PAX6 polymorphisms with myopia, and a 
recent meta-analysis concluded that PAX6 may confer only 
a small effect, if any, to myopia development [48]. Further 
studies are needed to clarify the potential involvement of 
PAX6 in myopia.
One novel variant, p.(Met1?), was predicted to abolish 
the initiation codon and was considered deleterious. Although 
this variant has not been previously reported, other variants 
affecting the initiation codon of PAX6 have been described 
with aniridia [24,25,49]. In the present study, individual 15 
carrying variant p.(Met1?) had total aniridia, cataracts, and 
glaucoma. The phenotype associated with the different vari-
ants affecting the initiation codon does not seem to differ 
from variants resulting in premature termination codons 
[24,25,49].
One proband carried a missense variant predicted to 
be deleterious in exon 5, p.(Ile29Thr)). Missense variants 
associated with aniridia occur more often in exons 5–6 that 
encode the paired domain important for DNA binding [13]. 
A previous study showed that missense variants can affect 
protein stability or impair DNA-binding ability [50]. More 
recently, Xie et al. demonstrated that missense variants can 
affect the ability of the protein to activate its target genes [51]. 
Two other variants affecting the same codon, p.(Ile29Val) and 
p.(Ile29Ser), have been reported in patients with aniridia in 
the Human PAX6 Allelic Variant Database. Missense variants 
have been described in individuals with a range of ocular 
phenotypes from aniridia to milder non-aniridia phenotypes, 
including optic nerve anomalies, Peters’ anomaly, corectopia, 
and foveal hypoplasia [13]. Missense variants have been 
associated with better visual acuity due to the lower rate of 
associated features [2]. In this study, individual 6 carrying the 
p.(Ile29Thr) novel variant had visual acuities better than 1.00 
logMAR, but he presented total aniridia, glaucoma, cataracts, 
foveal hypoplasia, and nystagmus, which does not suggest a 
milder phenotype.
We identified five deletions of the PAX6 gene using 
MLPA, one partial and four total deletions, as well as one 
deletion distal of PAX6. The partial PAX6 deletion involved 
the last two exons of the gene, resulting in a truncated protein. 
Three total PAX6 deletions did not encompass WT1, there-
fore, confirming a diagnosis of isolated aniridia. The other 
total deletion was part of a larger chromosomal deletion on 
chromosome 11p (p13-p15) as shown by the karyotype. The 
phenotype of the patient (individual 7) included aniridia, 
obesity, mild intellectual impairment, and IgA nephropathy, 
which is consistent with a diagnosis of WAGRO syndrome. 
The karyotypes of both parents were normal suggesting a de 
novo occurrence of the chromosomal deletion.
We identified one deletion in mosaic in 30% cells from 
blood. Mosaic PAX6 deletions have been associated with 
milder phenotypes in some patients with low mosaicism: a 
10 Mb deletion in 28% cells was reported in an individual 
with coloboma [52] and a 5.28 Mb deletion in 45% cells was 
identified in an individual with mild WAGR syndrome [53]. 
In comparison, bilateral aniridia and optic atrophy were 
present in two individuals with a 200 kb deletion in 50% and 
60% cells [54]. In this study, individual 5 had bilateral total 
aniridia with a deletion identified in 30% cells. However, the 
phenotype associated with mosaic PAX6 deletion is deter-
mined by the ocular tissue whereas the deletion was detected 
in cells from blood. Therefore, it is possible that the deletion 
is present in a greater proportion in ocular tissues, accounting 
for the more severe phenotype.
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A deletion distal of PAX6 was identified in one patient 
(individual 13). Deletions downstream of PAX6 that leave the 
PAX6 gene intact have been reported in some patients with 
aniridia [17,55]. These deletions abolish PAX6 expression and 
cause aniridia in patients due to the loss of an evolutionary 
conserved regulatory region containing tissue specific 
enhancers that are essential for PAX6 expression [17].
The detection rate is similar to other studies that reported 
intragenic variants and chromosomal rearrangements in 
approximately 90% of patients with aniridia [14,15]. No PAX6 
variant or copy number variation could be demonstrated in 
one of the 18 probands (5.6%) with aniridia (individual 14 
from Sri Lanka). His phenotype was not different from the 
other probands in the cohort. He had a visual acuity of hand 
motion in the right eye due to cataract and a subluxed lens, 
and had no perception of light in his left eye due to compli-
cation of cataract surgery resulting in a phthisical eye. His 
father was reported as having aniridia but was not available 
for examination. A single nucleotide substitution located 
in PAX6 regulatory elements has been previously reported 
in an individual with aniridia [56]. Therefore, it is possible 
that deletions or variants distal of PAX6, or variants in other 
genes, may account for the aniridia in the unsolved case.
In conclusion, we reported a detection rate of 94% for 
variants and deletions in PAX6 in individuals with aniridia 
from Australasia and Southeast Asia. To the best of our 
knowledge, this study is the first description of aniridia and 
PAX6 variations in individuals from Cambodia, Sri Lanka, 
Bhutan, and New Caledonia. These results support the obser-
vation of marked allelic heterogeneity and high prevalence 
of loss of function variants within PAX6-related aniridia. 
Molecular diagnosis can assist in the clinical management of 
affected patients and may be essential to future clinical trials.
APPENDIX 1. PRIMERS USED FOR 
AMPLIFICATION OF THE PAX6 GENE.
To access the data, click or select the words “Appendix 1”
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